This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The fields of artificial intelligence (AI) and machine learning (ML) are increasingly influencing clinical research and development (R&D). Contract research organizations (CROs) and pharmaceutical companies can leverage these cutting-edge technologies to streamline clinical trials and introduce automation in drug discovery.
BioTechX also gave us the opportunity to broaden the depth of our understanding of biotechnology, precision medicine, how folks are using data in their biomedical research, and so much more. Highlights include an examination of clinical trial termination reasons and an exploration of novel target groups.
Clinical trial success is a key factor for pharma companies when designing and recruiting patients into trials. This data can also provide guidance in terms of diversifying clinical trials to include different types of population demographics such as age, gender, race, ethnicity, or geographic location.
Breaking Down Barriers to International Clinical Trials Global Disruptions, Health Equity & Data Sharing As the U.S. When time is of the essence, like in a global pandemic, how do you scale trials internationally for success? Additionally, clinical trials are no longer confined to one country or region.
In today’s world of research, using a clinical trial management system (CTMS) can significantly streamline operations, and make for a more efficient research study. Configuring protocol milestones also triggers notifications for coordinators overseeing many parallel trials. Want to learn more?
Streamline your operations and improve trial feasibility and outcomes. Clinical Research Organizations (CROs) play an important role in the success of clinical trials. They provide crucial resources, processes, and strategies to ensure that trials are conducted with the highest standards of accuracy and data quality.
For life sciences companies, the application of AI has the potential to provide transformative value, not only in terms of direct financial return but also through operational, research, and clinical advancements. For more information on how to integrate AI into your workflow, request a demo.
Increasing diversity in clinical trials not only makes the findings more relevant to various patient groups, but also enhances knowledge about the disease or medical product being studied. The recent draft by the FDA introduces additional guidelines for Diversity Action Plans aimed at improving diversity in clinical research.
Breaking the Barriers: How Inaccurate Trial Records Are Delaying Drug Development and Limiting Diverse Patient Populations In an October 2023 report , BMC Medicine completed a follow-up on a 10-year effort to understand, report on and track data sharing challenges with big pharma, specifically for clinical trials.
The success of drug development and approval relies heavily on the ability to identify diverse patient populations for clinical trials. From trial site feasibility to successful trial recruitment, diversity within a trial population helps ensure the safety and efficacy of drugs that reach the market. African Americans).
In November and December, several large pharmas held “AI Day” presentations featuring LLM applications for clinical trial data analysis. Aside from some very brief demos on code generation and literature searches, mentions of LLM applications in preclinical research were scarce.
A live demo is available online, but “it chews through OpenAI credits,” Patel says. Goodsell, Scripps Research and RCSB Protein Data Bank. There’s a live demo available online. “Right now, it can only make one protein at a time,” Gershon says, simply because the demo has limited compute resources.
A live demo is available online, but “it chews through OpenAI credits,” Patel says. Goodsell, Scripps Research and RCSB Protein Data Bank. There’s a live demo available online. “Right now, it can only make one protein at a time,” Gershon says, simply because the demo has limited compute resources.
Codon Digest is my weekly roundup of research, news, and industry highlights about engineered biology. The researchers first compared the editing efficiency of different versions of IscB when coupled with 'ωRNA,' which guides the enzyme to the right spot on the DNA. Nucleic Acids Research. Please send me your feedback.
Codon Digest is my weekly roundup of research, news, and industry highlights about engineered biology. The researchers first compared the editing efficiency of different versions of IscB when coupled with 'ωRNA,' which guides the enzyme to the right spot on the DNA. Nucleic Acids Research. Please send me your feedback.
Conference ( OPEN ) European Federation of Pharmaceutical Industries and Associations (EFPIA) 6/04/2024 6/05/2024 Third listen-and-learn focus group meeting of the Quality Innovation Group Webinar/Seminar ( OPEN ) EMA Quality Innovation Group (QIG) 6/05/2024 6/05/2024 Procurement Working Party Committee Meeting ( CLOSED ) British In Vitro Diagnostics (..)
How will AI impact clinical trials? Pharmaceutical companies are on the brink of a tech revolution, and will embrace AI as a means to enhance their operations and research capabilities. Imagine a healthcare world where medical research is crystal clear and open to all, making science feel like a breeze.
Comment periods for EMA documents (such as concept, reflection, and guidance papers) generally stay open for at least six months, though these timelines can vary drastically. policy, such as public registers, drafts, reflection papers, concept papers, and guidance documents expected into Q1 2024.
Selecting an electronic institutional review board (eIRB) system is a critical decision for institutions looking to streamline their research compliance processes. Navigating the eIRB landscape can be overwhelming for researchers, human research protection program (HRPP) team members, and institutions alike.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content